225 related articles for article (PubMed ID: 25715384)
1. Harmonization of HTA--based reimbursement and regulatory approval activities: a qualitative study.
Tsoi B; O'Reilly D; Masucci L; Drummond M; Goeree R
J Popul Ther Clin Pharmacol; 2015; 22(1):e78-89. PubMed ID: 25715384
[TBL] [Abstract][Full Text] [Related]
2. Harmonization of reimbursement and regulatory approval processes: a systematic review of international experiences.
Tsoi B; Masucci L; Campbell K; Drummond M; O'Reilly D; Goeree R
Expert Rev Pharmacoecon Outcomes Res; 2013 Aug; 13(4):497-511. PubMed ID: 23977976
[TBL] [Abstract][Full Text] [Related]
3. Policies for Use of Real-World Data in Health Technology Assessment (HTA): A Comparative Study of Six HTA Agencies.
Makady A; Ham RT; de Boer A; Hillege H; Klungel O; Goettsch W;
Value Health; 2017 Apr; 20(4):520-532. PubMed ID: 28407993
[TBL] [Abstract][Full Text] [Related]
4. International comparison of comparative effectiveness research in five jurisdictions: insights for the US.
Levy AR; Mitton C; Johnston KM; Harrigan B; Briggs AH
Pharmacoeconomics; 2010; 28(10):813-30. PubMed ID: 20831289
[TBL] [Abstract][Full Text] [Related]
5. Health Technology Assessment (HTA) Case Studies: Factors Influencing Divergent HTA Reimbursement Recommendations in Australia, Canada, England, and Scotland.
Allen N; Walker SR; Liberti L; Salek S
Value Health; 2017 Mar; 20(3):320-328. PubMed ID: 28292476
[TBL] [Abstract][Full Text] [Related]
6. Building Synergy between Regulatory and HTA Agencies beyond Processes and Procedures-Can We Effectively Align the Evidentiary Requirements? A Survey of Stakeholder Perceptions.
Wang T; McAuslane N; Liberti L; Leufkens H; Hövels A
Value Health; 2018 Jun; 21(6):707-714. PubMed ID: 29909876
[TBL] [Abstract][Full Text] [Related]
7. A regulatory governance perspective on Health Technology Assessment (HTA) in Sweden.
Shah SM; Barron A; Klinger C; Wright JS
Health Policy; 2014 May; 116(1):27-36. PubMed ID: 24655685
[TBL] [Abstract][Full Text] [Related]
8. Health technology assessment of medicines in Greece: pharmaceutical industry executives' views.
Armataki E; Karampli E; Kyriopoulos J; Pavi E
Int J Technol Assess Health Care; 2014 Apr; 30(2):226-32. PubMed ID: 24806287
[TBL] [Abstract][Full Text] [Related]
9. A regulatory governance perspective on health technology assessment (HTA) in France: the contextual mediation of common functional pressures.
Barron AJ; Klinger C; Shah SM; Wright JS
Health Policy; 2015 Feb; 119(2):137-46. PubMed ID: 25458970
[TBL] [Abstract][Full Text] [Related]
10. 'The problem is small enough, the problem is big enough': a qualitative study of health technology assessment and public policy on drug funding decisions for children.
Denburg AE; Giacomini M; Ungar WJ; Abelson J
Int J Equity Health; 2020 Mar; 19(1):45. PubMed ID: 32228588
[TBL] [Abstract][Full Text] [Related]
11. Harmonization of evidence requirements for health technology assessment in reimbursement decision making.
Hutton J; Trueman P; Facey K
Int J Technol Assess Health Care; 2008; 24(4):511-7. PubMed ID: 18828948
[TBL] [Abstract][Full Text] [Related]
12. Patient Preferences in the Medical Product Life Cycle: What do Stakeholders Think? Semi-Structured Qualitative Interviews in Europe and the USA.
Janssens R; Russo S; van Overbeeke E; Whichello C; Harding S; Kübler J; Juhaeri J; Bywall KS; Comanescu A; Hueber A; Englbrecht M; Nikolenko N; Pravettoni G; Simoens S; Stevens H; Hermann R; Levitan B; Cleemput I; de Bekker-Grob E; Veldwijk J; Huys I
Patient; 2019 Oct; 12(5):513-526. PubMed ID: 31222436
[TBL] [Abstract][Full Text] [Related]
13. Regulating biotechnology: a rational-political model of policy development.
Wiktorowicz M; Deber R
Health Policy; 1997 May; 40(2):115-38. PubMed ID: 10167067
[TBL] [Abstract][Full Text] [Related]
14. Health Technology Assessment Development in Vietnam: A Qualitative Study of Current Progress, Barriers, Facilitators, and Future Strategies.
Lee HY; Nguyen TT; Park S; Hoang VM; Kim WH
Int J Environ Res Public Health; 2021 Aug; 18(16):. PubMed ID: 34444597
[TBL] [Abstract][Full Text] [Related]
15. Interaction initiatives between regulatory, health technology assessment and coverage bodies, and industry.
Frønsdal K; Pichler F; Mardhani-Bayne L; Henshall C; Røttingen JA; Mørland B; Klemp M
Int J Technol Assess Health Care; 2012 Oct; 28(4):374-81. PubMed ID: 23062516
[TBL] [Abstract][Full Text] [Related]
16. Emergent patterns in the regulation of pharmaceuticals: institutions and interests in the United States, Canada, Britain, and France.
Wiktorowicz ME
J Health Polit Policy Law; 2003 Aug; 28(4):615-58. PubMed ID: 12956518
[TBL] [Abstract][Full Text] [Related]
17. Formal Implementation of Cost-Effectiveness Evaluations in Japan: A Unique Health Technology Assessment System.
Hasegawa M; Komoto S; Shiroiwa T; Fukuda T
Value Health; 2020 Jan; 23(1):43-51. PubMed ID: 31952673
[TBL] [Abstract][Full Text] [Related]
18. Economic Evaluation for Pricing and Reimbursement of New Drugs in Spain: Fable or Desideratum?
Oliva-Moreno J; Puig-Junoy J; Trapero-Bertran M; Epstein D; Pinyol C; Sacristán JA
Value Health; 2020 Jan; 23(1):25-31. PubMed ID: 31952669
[TBL] [Abstract][Full Text] [Related]
19. Use of Real-World Data Sources for Canadian Drug Pricing and Reimbursement Decisions: Stakeholder Views and Lessons for Other Countries.
Husereau D; Nason E; Ahuja T; Nikaï E; Tsakonas E; Jacobs P
Int J Technol Assess Health Care; 2019 Jan; 35(3):181-188. PubMed ID: 31133089
[TBL] [Abstract][Full Text] [Related]
20. Increasing the Legitimacy of Tough Choices in Healthcare Reimbursement: Approach and Results of a Citizen Forum in The Netherlands.
Bijlmakers L; Jansen M; Boer B; van Dijk W; Groenewoud S; Zwaap J; Helderman JK; van Exel J; Baltussen R
Value Health; 2020 Jan; 23(1):32-38. PubMed ID: 31952671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
